342 related articles for article (PubMed ID: 26753656)
41. Effects of myo-inositol, gymnemic acid, and L-methylfolate in polycystic ovary syndrome patients.
Stracquadanio M; Ciotta L; Palumbo MA
Gynecol Endocrinol; 2018 Jun; 34(6):495-501. PubMed ID: 29265900
[TBL] [Abstract][Full Text] [Related]
42. Effect of body mass index on in vitro fertilization outcomes in women with polycystic ovary syndrome.
Bailey AP; Hawkins LK; Missmer SA; Correia KF; Yanushpolsky EH
Am J Obstet Gynecol; 2014 Aug; 211(2):163.e1-6. PubMed ID: 24657792
[TBL] [Abstract][Full Text] [Related]
43. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial.
Costantino D; Minozzi G; Minozzi E; Guaraldi C
Eur Rev Med Pharmacol Sci; 2009; 13(2):105-10. PubMed ID: 19499845
[TBL] [Abstract][Full Text] [Related]
44. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction.
Papaleo E; Unfer V; Baillargeon JP; De Santis L; Fusi F; Brigante C; Marelli G; Cino I; Redaelli A; Ferrari A
Gynecol Endocrinol; 2007 Dec; 23(12):700-3. PubMed ID: 17952759
[TBL] [Abstract][Full Text] [Related]
45. Comparison of oocyte quality and intracytoplasmic sperm injection outcome in women with isolated polycystic ovaries or polycystic ovarian syndrome.
Sahu B; Ozturk O; Ranierri M; Serhal P
Arch Gynecol Obstet; 2008 Mar; 277(3):239-44. PubMed ID: 17899140
[TBL] [Abstract][Full Text] [Related]
46. Biotechnological and clinical outcome of in vitro fertilization in non-obese patients with polycystic ovarian syndrome.
Ciepiela P; Baczkowski T; Brelik P; Antonowicz A; Safranow K; Kurzawa R
Folia Histochem Cytobiol; 2007; 45 Suppl 1():S65-71. PubMed ID: 18292838
[TBL] [Abstract][Full Text] [Related]
47. Potential role and therapeutic interests of myo-inositol in metabolic diseases.
Croze ML; Soulage CO
Biochimie; 2013 Oct; 95(10):1811-27. PubMed ID: 23764390
[TBL] [Abstract][Full Text] [Related]
48. Impact of body mass index on intracytoplasmic sperm injection in women with polycystic ovary syndrome.
Kamardi S; Surya IHW; Mahendra INB; Adnyana IP; Suardika A; Tondohusodo N; Sudiman J
Zygote; 2021 Jun; 29(3):229-233. PubMed ID: 33455589
[TBL] [Abstract][Full Text] [Related]
49. Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS.
Pizzo A; Laganà AS; Barbaro L
Gynecol Endocrinol; 2014 Mar; 30(3):205-8. PubMed ID: 24351072
[TBL] [Abstract][Full Text] [Related]
50. The effect of Myo-inositol on fertility rates in poor ovarian responder in women undergoing assisted reproductive technique: a randomized clinical trial.
Mohammadi S; Eini F; Bazarganipour F; Taghavi SA; Kutenaee MA
Reprod Biol Endocrinol; 2021 Apr; 19(1):61. PubMed ID: 33892722
[TBL] [Abstract][Full Text] [Related]
51. Effects of myo-inositol plus alpha-lactalbumin in myo-inositol-resistant PCOS women.
Montanino Oliva M; Buonomo G; Calcagno M; Unfer V
J Ovarian Res; 2018 May; 11(1):38. PubMed ID: 29747700
[TBL] [Abstract][Full Text] [Related]
52. Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients.
Genazzani AD; Prati A; Santagni S; Ricchieri F; Chierchia E; Rattighieri E; Campedelli A; Simoncini T; Artini PG
Gynecol Endocrinol; 2012 Dec; 28(12):969-73. PubMed ID: 22612517
[TBL] [Abstract][Full Text] [Related]
53. Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study.
Kjøtrød SB; von Düring V; Carlsen SM
Hum Reprod; 2004 Jun; 19(6):1315-22. PubMed ID: 15117902
[TBL] [Abstract][Full Text] [Related]
54. Vitamin D improves in-vitro fertilization outcomes in infertile women with polycystic ovary syndrome and insulin resistance.
Zhao J; Liu S; Wang Y; Wang P; Qu D; Liu M; Ma W; Li Y
Minerva Med; 2019 Jun; 110(3):199-208. PubMed ID: 30612423
[TBL] [Abstract][Full Text] [Related]
55. Exposure to human chorionic gonadotropin during in vitro maturation does not improve the maturation rate and developmental potential of immature oocytes from patients with polycystic ovary syndrome.
Ge HS; Huang XF; Zhang W; Zhao JZ; Lin JJ; Zhou W
Fertil Steril; 2008 Jan; 89(1):98-103. PubMed ID: 17524398
[TBL] [Abstract][Full Text] [Related]
56. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone.
Nordio M; Proietti E
Eur Rev Med Pharmacol Sci; 2012 May; 16(5):575-81. PubMed ID: 22774396
[TBL] [Abstract][Full Text] [Related]
57. [Effect of electroacupuncture on oocyte quality and pregnancy for patients with PCOS undergoing in vitro fertilization and embryo transfervitro fertilization and embryo transfer].
Cui W; Li J; Sun W; Wen J
Zhongguo Zhen Jiu; 2011 Aug; 31(8):687-91. PubMed ID: 21894688
[TBL] [Abstract][Full Text] [Related]
58. The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome.
Dinicola S; Chiu TT; Unfer V; Carlomagno G; Bizzarri M
J Clin Pharmacol; 2014 Oct; 54(10):1079-92. PubMed ID: 25042908
[TBL] [Abstract][Full Text] [Related]
59. Insulin resistance does not affect early embryo development but lowers implantation rate in in vitro maturation-in vitro fertilization-embryo transfer cycle.
Chang EM; Han JE; Seok HH; Lee DR; Yoon TK; Lee WS
Clin Endocrinol (Oxf); 2013 Jul; 79(1):93-9. PubMed ID: 23176069
[TBL] [Abstract][Full Text] [Related]
60. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study.
Artini PG; Di Berardino OM; Papini F; Genazzani AD; Simi G; Ruggiero M; Cela V
Gynecol Endocrinol; 2013 Apr; 29(4):375-9. PubMed ID: 23336594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
